Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, affect several million individuals worldwide. These diseases are heterogeneous at the clinical, immunological and genetic levels and result from complex host and environmental interactions. Investigating drug...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0263248&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849707910805848064 |
|---|---|
| author | Laura-Jayne Gardiner Anna Paola Carrieri Karen Bingham Graeme Macluskie David Bunton Marian McNeil Edward O Pyzer-Knapp |
| author_facet | Laura-Jayne Gardiner Anna Paola Carrieri Karen Bingham Graeme Macluskie David Bunton Marian McNeil Edward O Pyzer-Knapp |
| author_sort | Laura-Jayne Gardiner |
| collection | DOAJ |
| description | Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, affect several million individuals worldwide. These diseases are heterogeneous at the clinical, immunological and genetic levels and result from complex host and environmental interactions. Investigating drug efficacy for IBD can improve our understanding of why treatment response can vary between patients. We propose an explainable machine learning (ML) approach that combines bioinformatics and domain insight, to integrate multi-modal data and predict inter-patient variation in drug response. Using explanation of our models, we interpret the ML models' predictions to infer unique combinations of important features associated with pharmacological responses obtained during preclinical testing of drug candidates in ex vivo patient-derived fresh tissues. Our inferred multi-modal features that are predictive of drug efficacy include multi-omic data (genomic and transcriptomic), demographic, medicinal and pharmacological data. Our aim is to understand variation in patient responses before a drug candidate moves forward to clinical trials. As a pharmacological measure of drug efficacy, we measured the reduction in the release of the inflammatory cytokine TNFα from the fresh IBD tissues in the presence/absence of test drugs. We initially explored the effects of a mitogen-activated protein kinase (MAPK) inhibitor; however, we later showed our approach can be applied to other targets, test drugs or mechanisms of interest. Our best model predicted TNFα levels from demographic, medicinal and genomic features with an error of only 4.98% on unseen patients. We incorporated transcriptomic data to validate insights from genomic features. Our results showed variations in drug effectiveness (measured by ex vivo assays) between patients that differed in gender, age or condition and linked new genetic polymorphisms to patient response variation to the anti-inflammatory treatment BIRB796 (Doramapimod). Our approach models IBD drug response while also identifying its most predictive features as part of a transparent ML precision medicine strategy. |
| format | Article |
| id | doaj-art-18c9b8372d2f4dba82ffe98cb346708f |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-18c9b8372d2f4dba82ffe98cb346708f2025-08-20T03:15:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01172e026324810.1371/journal.pone.0263248Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.Laura-Jayne GardinerAnna Paola CarrieriKaren BinghamGraeme MacluskieDavid BuntonMarian McNeilEdward O Pyzer-KnappInflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, affect several million individuals worldwide. These diseases are heterogeneous at the clinical, immunological and genetic levels and result from complex host and environmental interactions. Investigating drug efficacy for IBD can improve our understanding of why treatment response can vary between patients. We propose an explainable machine learning (ML) approach that combines bioinformatics and domain insight, to integrate multi-modal data and predict inter-patient variation in drug response. Using explanation of our models, we interpret the ML models' predictions to infer unique combinations of important features associated with pharmacological responses obtained during preclinical testing of drug candidates in ex vivo patient-derived fresh tissues. Our inferred multi-modal features that are predictive of drug efficacy include multi-omic data (genomic and transcriptomic), demographic, medicinal and pharmacological data. Our aim is to understand variation in patient responses before a drug candidate moves forward to clinical trials. As a pharmacological measure of drug efficacy, we measured the reduction in the release of the inflammatory cytokine TNFα from the fresh IBD tissues in the presence/absence of test drugs. We initially explored the effects of a mitogen-activated protein kinase (MAPK) inhibitor; however, we later showed our approach can be applied to other targets, test drugs or mechanisms of interest. Our best model predicted TNFα levels from demographic, medicinal and genomic features with an error of only 4.98% on unseen patients. We incorporated transcriptomic data to validate insights from genomic features. Our results showed variations in drug effectiveness (measured by ex vivo assays) between patients that differed in gender, age or condition and linked new genetic polymorphisms to patient response variation to the anti-inflammatory treatment BIRB796 (Doramapimod). Our approach models IBD drug response while also identifying its most predictive features as part of a transparent ML precision medicine strategy.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0263248&type=printable |
| spellingShingle | Laura-Jayne Gardiner Anna Paola Carrieri Karen Bingham Graeme Macluskie David Bunton Marian McNeil Edward O Pyzer-Knapp Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. PLoS ONE |
| title | Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. |
| title_full | Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. |
| title_fullStr | Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. |
| title_full_unstemmed | Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. |
| title_short | Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. |
| title_sort | combining explainable machine learning demographic and multi omic data to inform precision medicine strategies for inflammatory bowel disease |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0263248&type=printable |
| work_keys_str_mv | AT laurajaynegardiner combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease AT annapaolacarrieri combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease AT karenbingham combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease AT graememacluskie combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease AT davidbunton combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease AT marianmcneil combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease AT edwardopyzerknapp combiningexplainablemachinelearningdemographicandmultiomicdatatoinformprecisionmedicinestrategiesforinflammatoryboweldisease |